Why Iron is Drawn in Heart Failure
Iron status should be routinely assessed in all heart failure patients because iron deficiency is extremely common (affecting 40-70% of patients), directly impairs exercise capacity and quality of life independent of anemia, and is a treatable condition that improves clinical outcomes when corrected with intravenous iron therapy. 1, 2
High Prevalence and Clinical Impact
Iron deficiency occurs in approximately 50% of chronic heart failure patients, making it one of the most common comorbidities—comparable in frequency to anemia itself 1, 3. This prevalence is remarkably high regardless of:
- Gender, race, or left ventricular ejection fraction
- Presence or absence of anemia (iron deficiency can exist without anemia)
- Heart failure severity, though prevalence increases with higher NYHA class 4, 3
Critically, iron deficiency is an independent predictor of mortality and hospitalizations, with stronger predictive power than anemia itself 3. Patients with iron deficiency experience:
- Reduced exercise capacity
- Increased fatigue and symptom burden
- Higher hospitalization rates for heart failure
- Increased overall and cardiovascular mortality 1, 4
Why Iron Deficiency Develops in Heart Failure
The mechanisms are multifactorial and heart failure-specific 2:
Absolute Iron Deficiency
- Malabsorption from intestinal edema and reduced gut perfusion
- Malnutrition and dietary restrictions (including meat-free diets)
- Gastrointestinal blood loss exacerbated by anticoagulants, antiplatelets, and NSAIDs
Functional Iron Deficiency (More Common in HF)
- Chronic inflammation with elevated cytokines increases hepatic hepcidin production
- Hepcidin blocks iron absorption from the GI tract and iron mobilization from storage sites (reticuloendothelial system)
- Impaired iron utilization despite adequate stores
- Coexisting renal dysfunction further compounds the problem 2
Guideline-Recommended Screening Approach
Both the 2022 AHA/ACC/HFSA and 2016 ESC guidelines recommend routine iron status evaluation in all heart failure patients 1, 2:
When to Screen
- At initial heart failure diagnosis (Class I recommendation)
- In existing chronic HF patients who remain symptomatic despite optimal medical therapy
- Routinely 1-2 times per year during follow-up
- After hospitalization for heart failure 2
What to Order
Always order both ferritin AND transferrin saturation (TSAT) simultaneously—they must be evaluated together 2:
Iron deficiency is defined as:
- Ferritin <100 μg/L (absolute deficiency), OR
- Ferritin 100-299 μg/L with TSAT <20% (functional deficiency)
Common Pitfalls to Avoid
- Do NOT use lower ferritin cutoffs (e.g., <30 μg/L) that apply to other populations—heart failure requires higher thresholds due to inflammation 2
- Do NOT rely on MCV, MCH, or MCHC—these are unreliable markers in heart failure 2
- Do NOT use serum iron alone—it has large diurnal variations and is unreliable 2
- Do NOT assume normal hemoglobin excludes iron deficiency—50% of iron-deficient HF patients are not anemic 1, 3
Why This Matters: Treatment Implications
Intravenous iron therapy improves exercise capacity, quality of life, NYHA class, and reduces heart failure hospitalizations 1. The 2022 AHA/ACC/HFSA guidelines cite multiple trials (FAIR-HF, CONFIRM-HF, AFFIRM-AHF) demonstrating these benefits 1. Notably:
- Oral iron does NOT work in heart failure due to poor absorption and inadequate repletion (IRONOUT HF trial) 1
- Only intravenous iron (ferric carboxymaltose) is effective 1, 4
- Benefits occur independent of anemia status 1, 2
- AFFIRM-AHF showed 26% reduction in HF hospitalizations (RR 0.74,95% CI 0.58-0.94) 1
The Bottom Line
Iron deficiency is uniquely associated with reduced exercise capacity in heart failure 1. Unlike many comorbidities that lack specific treatments, iron deficiency is both highly prevalent and highly treatable with proven mortality and morbidity benefits. Failure to screen means missing a therapeutic opportunity that directly improves patient quality of life and clinical outcomes—this is why iron studies are now considered standard of care in heart failure evaluation 1, 2.